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Abstract
Objective—Compare the efficacy of surrogate or gestational carrier (GC) cycles to that of 
autologous in vitro fertilization (IVF)/intracytoplasmic sperm injections (ICSI) in patients with 
gynecologic or medical co-morbidities contraindicative to pregnancy.
Design—Retrospective cohort study.
Setting—Infertility patients from a single university hospital-based program from 1998-2009.
Intervention(s)—128 GC cycles from 80 intended parents were identified and compared with 
15,311 IVF or ICSI cycles.
Main Outcome Measure(s)—The peak estradiol (E2), number of oocytes retrieved, cycle 
cancellation, ongoing pregnancy, and live-birth were compared between GCs and autologous IVF 
carriers. Indications for GC use were also identified. Multiple cycles contributed by the same 
patient were accounted for using multivariable generalized estimating equations and two-sided 
Wald p-values.
Results—Uterine factors (67%) was the most common indication for using a GC, followed by 
non-gynecologic medical conditions including coagulopathies (13%), end stage renal disease 
(10%), cardiovascular disease (5%) and cancer (5%). Adjusting for age, ovulation induction in GC 
cycles had similar peak E2 levels and number of oocytes retrieved relative to IVF cycles (p = 0.23 
and 0.43, respectively). Clinical pregnancy (49% vs. 42%, p = 0.28) and live-birth rates (31% vs. 
32%, p = 0.74) were also comparable. A sub-analysis of GC cycles in those women with uterine 
factor indications, demonstrated significantly higher clinical pregnancy rates (OR = 2.0; CI = 1.2 - 
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3.5) with 60% greater odds of live-birth relative to IVF/ICSI cycles, however this odds was not 
statistically significant for differences in live-birth (CI = 0.9 - 2.9). Conclusions: GCs are a viable 
alternative to start families for patients with medical co-morbidities precluding pregnancy.
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1. INTRODUCTION
The physiologic changes and demands associated with pregnancy place significant stress on 
women. In addition to increased demands on cardiovascular output, renal function and 
glucose metabolism, physical stresses associated with labor and delivery are better tolerated 
if the patient is healthy at conception. Childbearing is often deferred to later stages of life for 
a variety of reasons including primary or secondary infertility, iatrogenic infertility, non-
obstetrical medical morbidity and socioeconomic conditions [1-12]. Accordingly there is a 
need for alternatives to conventional childbearing for establishing one’s family to address 
many of the age related physiologic changes women undergo.
The most comprehensive data regarding GC pregnancies stem from the European experience 
[3,7,13,14]. Earliest reports indicated clinical pregnancy rates of 18% [13,15], in cycles 
utilizing gestational carriers. However the notion of employing the assistance of others to 
conceive is ancient and is seen in the practice of having concubines help infertile women 
bear children in several early cultures including the Romans, Greeks and Chinese [16]. By 
definition a surrogate mother is one who provides her oocytes as well as uterus for the 
pregnancy [1, 13], while a gestational carrier is an individual who carries a non-biologic 
child for another intended parent (IP) and therefore only has a gestational relationship to the 
child [1,9,15]. The pregnancy thus is a result of an in vitro fertilization process using the 
IP’s gametes and then transferring the embryo(s) to the GC’s uterus. If the IP is unable to 
safely carry a pregnancy due to co-morbid conditions such as cardiac disease, severe 
osteoporosis, endometrial scarring from radiation therapy or surgery related to cancer, as 
examples, the use of a GC affords her the opportunity to have a genetically related child.
While the notion of using gestational carriers (GCs) is an attractive and seemingly safe 
option, there is a paucity of data examining the delivery success rates, because of the 
pregnancy or impact on the GC. In this study we examine the increasing practice of GC 
pregnancies and evaluate the efficacy of GCs in assisted reproductive technology.
2. MATERIALS AND METHODS
We conducted a retrospective cohort study including IVF cycles from 1998-2009 at a single 
university hospital-based infertility clinic with Institutional Review Board (IRB) approval 
(IRB # 2011p001000). During this 12 year period, 128 GC cycles were identified from 80 
intended parents. The comparison group included 15,311 fresh IVF cycles from 7780 
different women during this same time period. Cycles employing GIFT, ZIFT, oocyte 
donation, day 5 embryo transfer or cryo-embryo transfers were excluded. Cycles for women 
<25 years old and those who used a gestational carrier electively for non-medical indications 
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(social reasons i.e. same sex couples) were also excluded from the study cohort Criteria for 
IVF acceptance are: day 3 FSH and E2, TSH < 3.0 mIU/L, normal uterine cavity for non-GC 
cycles. (There is no absolute FSH cut off in our program, however women with FSH levels 
> 10 IU/ L generally underwent poor responder protocols). Stimulation protocols used 
included a long leuprolide down regulation protocol, GnRH antagonist protocol which 
included 7 - 21 days of oral contraceptive pretreatment, and for poor responder’s microflare 
or estrogen priming-antagonist stimulations. Stimulation included with 150 - 600 IU FSH 
per day starting dose, with or without additional LH which was administered as a human 
menopausal gonadotropin product. With the exception of three GCs who were 40.5, 40.7, 
and 42.2 years old, all of the remaining gestational carriers in this analysis were less than 40 
years old and must have had at least one term birth, no medical problems other than treated 
hypothyroidism, no history of miscarriage, or uterine surgery other than prior Cesarean 
section. Required FDA testing was rigorously adhered to in all cycles starting in 2005. 
These tests include immune screening for hepatitides (hepatitis B Surface antigen and 
hepatitis C core antibody), HTLV 1&2, HIV 1&2, Chla smydia, Gonorrhea, Syphilis (RPR), 
CMV (IgG, IgM), rubella and PAP smear screening.
3. OUTCOME DEFINITIONS
An ongoing pregnancy included patients who were discharged from the IVF practice to their 
Obstetrician or Gynecologist’s care with an intrauterine pregnancy detected via ultrasound 
with a fetal heart rate between 7 - 8 weeks of gestation. Pregnancy losses <12 weeks of 
gestation, chemical pregnancies and blighted ova were not considered to be ongoing 
pregnancies. Live-birth was defined as the birth of a live born infant at >20 weeks. Ongoing 
pregnancy and live-birth rates are reported per embryo transfer unless otherwise stated. A 
cancelled cycle indicated a poor response to hormonal stimulation during the IVF cycle and 
no oocyte retrieval or embryo transfer. Freeze all cycles were considered to be cancelled 
cycles and as previously indicated, cryo-embryo transfer cycles were excluded from the 
analysis.
4. STATISTICAL ANALYSIS
Generalized estimating equations that calculated odds ratios (OR) and 95% confidence 
intervals (CI) were used to account for the correlation between cycles with embryos from 
the same intended parents. The normal distribution with identity link was specified when 
studying peak estradiol, a Poisson distribution with log link for number of oocytes retrieved, 
and a binomial distribution with logit link for cycle cancellation, ongoing pregnancy, and 
live-birth. Continuous age in months was adjusted for in all models a priori. Peak estradiol 
(E2) was additionally adjusted for when evaluating number of oocytes retrieved, as the 
effect estimate changed by greater than 10% when peak E2 was added to the model. The 
addition of peak E2 and number of embryos transferred (ET) changed the effect estimate for 
post-ET outcomes negligibly, and therefore are not included in the final models for 
pregnancy and live-birth. All Wald p-values are 2-sided with <0.05 considered to be 
statistically significant. Analyses were performed using Statistical Analysis Software 
(SAS®) version 9.1 (SAS Institute, Inc., Cary, NC).
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5. RESULTS
A total of 128 GC cycles from 80 intended parents and 15,311 comparison IVF cycles from 
7780 women were included in the study population. The age distribution was similar 
between groups, with a median age of 36.6 years among GC cycle intended parents 
(interquartile range, Q1 - Q3: 32.7 - 39.0) and 36.7 years among IVF cycles (Q1 - Q3: 33.6 - 
39.6) (Table 1). Gestational carriers were between 21.6 and 42.2 years old, with a median 
age of 32.1 years (Q1 - Q3: 28.7 - 35.5).
The most common indication for using a gestational carrier was uterine factors (67%), 
followed by coagulopathies (13%), end stage renal disease (10%), cardiovascular disease 
(5%) and history of cancer (5%). The comparison IVF cycles consisted of few uterine-factor 
infertility diagnoses (3%). Other infertility diagnoses among the comparison group included 
tubal factor (18%), ovulatory dysfunction (6%), PCOS (4%), male factor (28%), other 
female factor (20%), and unexplained (22%) (Table 2).
GC cycles were stimulated similarly to the comparison IVF cycles. Both groups were 
stimulated for 11 days on average, with the GC group receiving a median of 3600 IU of 
gonadatropins (Q1 - Q3: 2100 - 4800) and the IVF group receiving a median of 3000 IU of 
gonadatropins (Q1 - Q3: 1800 - 4800 Compared to women undergoing IVF alone, the odds 
of cycle cancellation among women using GCs was not significantly different (OR = 1.45; 
95% CI = 0.71 - 2.94) (Table 3). Peak E2 and number of oocytes retrieved were also similar 
between groups (Wald, two-sided p-value = 0.23 and 0.43, respectively).
Pregnancy and live-birth rates also were comparable between the two groups. Among 
embryo transfers, GC cycles had 1.2 times the odds of ongoing pregnancy (95% CI = 0.84 - 
1.84) and 0.93 times the odds of live-birth (95% CI = 0.61 - 1.43), as compared to IVF 
cycles. Results were similar when looking at the overall ongoing pregnancy and live-birth 
rates per cycle start (data not shown).
It is possible that the effect of utilizing a GC on cycle outcomes is different depending on IP 
age, though this study was not powered to detect heterogeneity between age strata. 
Descriptive statistics seem to suggest that the considerable decrease in ongoing pregnancy 
rates with increased age that is well established among traditional IVF cycles may not have 
as great an impact in GC cycles (Table 4(a)). However, live-birth rates were still 
considerably lower among intended parents in their late thirties and older. Again, small 
numbers make it difficult to draw definitive conclusions from these age-stratified analyses. 
A sub analysis was conducted comparing women with uterine indications in the GC group to 
those with uterine factor diagnoses in the comparison group (non-GC; Table 4(b)). Of the 
total analyzed cycles, three cycles (n = 86, 3.5% OR = 0.53, 95% C = 0.15 - 1.81) and thirty 
cycles (n = 403, 7.4%) were cancelled in the GC and non-GC groups (Table 4(b)) 
respectively secondary to poor response to ovarian stimulation. Of the remaining completed 
cycles the odds of ongoing pregnancy were statistically significantly 2-fold greater among 
women who used GCs (OR = 2.03, 95% CI = 1.18 - 3.49), however the 1.6 times greater 
odds of live-birth among the GC cycles did not reach statistical significance (95% CI = 0.91 
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- 2.89). This may be due to inadequate power to identify a true difference due to the small 
sample size.
Age stratified clinical outcomes among the women with uterine factor diagnoses (Table 
4(b)) was also examined. As in the main analysis, there was some evidence of differential 
effect of GC by age, suggesting greater benefit of employing a GC among younger women 
with little benefit among older women-although the numbers are quite small within age-
specific strata. Descriptively, ongoing pregnancy rates between groups appear more 
discrepant among the younger age groups. Among patients aged 25 to 30, 23% (6/27) of 
comparison cycles versus 75% (3/4) of gestational carrier cycles had live-births; among 
patients over 35 years old, 17% (37/228) of comparison cycles and 18% (8/47) of gestational 
carrier cycles had live-births.
6. DISCUSSION
The indications for using a gestational carrier (GC) for pregnancy can be highly varied 
ranging from general medical conditions to congenital mullerian anomalies that preclude 
pregnancy (Table 2) [1-6,11,12]. While such health issues may not allow a woman to carry 
her own pregnancy, the patients’ overall gonadal fertility may be quite normal. With the 
wide spread availability of in vitro fertilization, the practice of employing GCs is becoming 
increasingly common. Furthermore the clinical indications for using a GC continue to 
expand. Accordingly it is important to better understand the efficacy of this treatment in 
different populations of intended parents. Additionally it is of interest to determine the 
relative contribution of the uterine environment to the success of a pregnancy independent of 
the IVF stimulation cycle.
Despite the small number of GC attempts in this study, to our knowledge this is currently 
one of the largest retrospective cohort studies that evaluate the efficacy of GC-cycles in 
patients undergoing assisted reproductive treatment at a single university hospital-based 
infertility clinic. In this retrospective cohort study, we observed that patients using a 
gestational carrier demonstrate a similar response to ovarian stimulation relative to other 
infertile couples undergoing a typical IVF/ICSI cycle as reflected by peak estradiol levels, 
amount of hormonal stimulation required to elicit a maximal response and number of 
oocytes retrieved. These observations held true despite differences in stimulation protocols 
employed in these patients. In our study we did not segregate patients based on individual 
variations in race, ethnicity or other non-medical characteristics. The total number of 
embryos transferred in both groups was comparable. As anticipated the pregnancy success 
rates remained associated with the intended parent’s age since this reflects the genetic 
contribution of the oocyte. These observations are consistent with several prior smaller 
studies that show GC live-birth rates to be higher than age-matched controls 
[1-3,7-10,13,15,17-25]. However in our study population, this difference was only evident 
among intended parents under age 35.
The implications of this result are various, including the observation that there might be an 
unrecognized uterine component contribution to the infertility of patients who are 
diagnostically classified to have diminished ovarian reserve, ovulatory dysfunction or 
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unexplained infertility. Such a putative uterine factor may also be related to age-dependent 
intrinsic properties of the maternal endometrium affecting implantation, placental growth, 
function and perfusion or the maternal immune response thereby impacting pregnancy 
outcomes in the infertile population [26-29]. By employing a GC, one or more of these 
factors are altered resulting in improved ongoing pregnancy rates. Thus it might be more 
informative to compare GC delivery rates and outcomes to the general obstetrical population 
than the infertile population of patients. If indeed the uterine milieu is improved in GC 
pregnancies who were selected because of their proven successful obstetrical histories, one 
would predict that the fetal outcomes should also reflect this in terms of fetal weight, and 
gestational age at time of delivery. A per cycle (not per patient) retrospective cohort analysis 
from the Society for Assisted Reproductive Technologies (SART) data base [25] supports 
such a hypothesis.
In this retrospective analysis of the SART database looking at obstetrical outcomes from 
2004-2006, differences in the uterine environment appeared to influence gestational age 
(GA) and birth weight (BW) with GC cycles faring better for BW than even donor egg (DE) 
cycles. This observation held true even when the uterine defect such as adhesions or 
leiomyomata were addressed prior to the initiation of fertility treatment. By contrast the GA 
in GCs was noted to be slightly less than either fresh IVF or DE cycles, consistent with the 
notion that the uterine environment might provide putative immunological factors 
influencing the duration of pregnancies. This latter result is curious and warrants further 
investigation.
In summary, our results demonstrate delivery rates comparable to that of the general IVF 
population when GCs are used to achieve a genetically related live-birth. Of equal 
importance is the observation that GC pregnancies are indeed a viable option for patient’s 
with comorbidities that would preclude them from carrying their own pregnancy. Thus while 
there are a host of ethical and social concerns one must consider prior to using a GC [30-44], 
gestational surrogacy does appear to benefit patients wanting to start a family who 
themselves have obstetrical contraindications precluding them from becoming pregnant. 
Furthermore, the use of GCs in patients with uterine indications resulting in miscarriages 
and pregnancy loss may prove to have higher ongoing pregnancy and live-birth rates. 
Further studies are needed to investigate the exact nature of the beneficial factors the GC 
uterus may be providing to contribute to these favorable ART outcomes as well as better 
understand the immunologic interplay between the placenta and the endometrial lining of 
the host uterus. Our ongoing investigations will address the influence of obstetrical 
complications such as preeclampsia or gestational diabetes on GCs [45,46], as such 
information would contribute to our understanding of the pathophysiology of these diseases 
and would be important to appropriately counsel intended parents and potential GCs 
regarding the risks and benefits of GC pregnancies.
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Table 1
Demographic characteristics by cycle type from a cohort of couples undergoing ART from 1998-2009 at a 
single university hospital-based infertility clinic.
Characteristic IVF(n = 15,311)
Gestational Carrier
(n = 128)
Patient age
N 15,311 128
Mean ± SD 36.4 ± 4.0 36.0 ± 4.1
Minimum-Maximum 25.0 - 43.9 27.2 - 43.9
Gestational carrier age
N 122
Mean ± SD - 32.0 ± 4.6
Minimum-Maximum 21.6 - 42.2
Cycle attempt number
N 15,311 128
Mean ± SD 1.9 ± 1.2 2.4 ± 1.8
Minimum-Maximum 1-10 1 - 9
Number of stimulation days
N 15,253 128
Mean ± SD 11.1 ± 2.1 11.8 ± 2.4
Minimum-Maximum 1 - 28 5 - 22
Total FSH (IU)
N 15,253 128
Mean ± SD 3330.0 ± 1868.5 3623.8 ± 1970.1
Minimum-Maximum 187.5 - 11700.0 337.5 - 11400.0
Number of embryos transferred
N 13,579 113
Mean ± SD 3.0 ± 1.6 3.1 ± 1.4
Minimum-Maximum 0 - 11 0 - 9
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Table 2
Descriptive statistics of cycle parameters and outcomes for 128 gestational carrier cycles, stratified by 
indication for gestational carrier use.
Indication for GC
Uterine Factor
(n = 86)
Medical Illness
(n = 42)
IP Age
N 86 42
Mean ± SD 36.3 ± 3.8 35.4 ± 4.6
Minimum-Maximum 27.2 - 43.9 28.8 - 43.8
Number of stimulation days
N 86 42
Mean ± SD 11.7 ± 2.3 11.8 ± 2.5
Minimum-Maximum 5 - 22 7 - 19
Total IU Of FSH
N 86 42
Mean + SD 3616 ± 2117 3639 ± 1654
Minimum-Maximum 450.0 - 11400 337.5 - 6600
Peak estradiol
N 86 40
Mean ± SD 2068 ± 997.7 2028 ± 1113
Minimum-Maximum 226 - 4708 33 - 4117
Number of oocytes retrieved
N 86 42
Mean ± SD 14.6 ± 8.2 11.6 ± 8.1
Minimum-Maximum 0 - 37 0 - 32
Number of embryos transferred
N 79 32
Mean ± SD 3.3 ± 1.4 3.0 (1.0)
Minimum-Maximum 2 - 9 2 - 6
Any embryos frozen
N 24 (27.9%) 14 (33.3%)
Cancelled cycle
N 3 (3.5%) 7 (16.7%)
Embryo transfer
N 79 (91.9%) 32 (76.2%)
Clinical pregnancy per cycle
N 37 (43.0%) 17 (40.5%)
Clinical pregnancy per ET
N 37 (46.8%) 17 (53.1%)
Live birth per cycle
N 22 (27.2%) 10 (26.3%)
Live birth per ET
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Indication for GC
Uterine Factor
(n = 86)
Medical Illness
(n = 42)
N 22 (29.7%) 10 (35.7%)
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Table 3
Cycle outcomes by gestational carrier use within a cohort of couples undergoing IVF at a university hospital-
based infertility clinic.
Outcome IVF (n = 15,311) Gestational Carrier (n = 128)
Cancelled cycle a
n (%) 876 (5.7%) 10 (7.8%)
OR (95% CI) 1.00 (Ref) 1.45 (0.71 - 2.94)
Peak estradiol b
N 14,517 126
Mean ± SD 1928.3 ± 977.1 2055.6 ± 1031.5
Median (Q1 - Q3) 1758.0 (1194.0 - 2528.0) 1881.5 (1322.0 - 2780.0)
p-value - 0.23
Number of oocytes retrieved c
N 14,385 128
Mean ± SD 13.6 ± 8.1 13.6 ± 8.3
Median (Q1 - Q3) 12.0 (8.0 - 18.0) 13.0 (6.5 - 19.5)
p-value, test for linear trend - 0.43
Clinical pregnancy per cycle a
n (%) 5703 (37.2%) 54 (42.2%)
OR (95% CI) 1.00 (Ref) 1.19 (0.82 - 1.73)
Clinical pregnancy per ET a
n (%) 5703 (42.4%) 54 (48.6%)
OR (95% CI) 1.00 (Ref) 1.24 (0.84 - 1.84)
Live-birth per cycle a
n (%) 4161 (28.1%) 32 (26.9%)
OR (95% CI) 1.00 (Ref) 0.90 (0.60 - 1.37)
Live-birth per ET a
n (%) 4161 (32.1%) 32 (31.4%)
OR (95% CI) 1.00 (Ref) 0.93 (0.61 - 1.43)
aOdds ratios (OR) and 95% confidence intervals (CI) are from generalized estimating equations accounting for correlation between cycles from the 
same woman, with a binomial outcome distribution and a logit link. Models are adjusted for continuous age. ET = embryo transfer, Clinical 
pregnancy = Ultrasound documented intrauterine pregnancy with fetal heart rate between 7 - 8 weeks gestation.
bp-values are from generalized estimating equations accounting for correlation between cycles from the same woman, with a normal outcome 
distribution and the identity link. Models are adjusted for continuous age.
cp-values are from generalized estimating equations accounting for correlation between cycles from the same woman, with a Poisson outcome 
distribution and a log link. Models are adjusted for continuous age and peak E2. For GC cycles, age is that of the intended parent.
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Table 4
Descriptive statistics of cycle outcomes stratified by gestational carrier use and age at cycle starta.
4(a) All cycles
25 - 30 years old 31 - 35 years old 36+ years old
IVF (n = 1594) GC (n = 13) IVF (n = 5058) GC (n = 46) IVF (n = 8659) GC (n = 69)
Cancelled cycle 48 (3.0%) 1 (7.7%) 228 (4.5%) 3 (6.5%) 600 (6.9%) 6 (8.7%)
Peak estradiol 2114 ± 1025 1866 ± 1141 1999 ± 977 2314 ± 1000 1851 ± 960 1914 ± 1011
Oocytes retrieved 16.8 ± 8.9 14.2 ± 8.5 14.8 ± 8.2 16.0 ± 7.9 12.3 ± 7.5 11.9 ± 8.1
Clinical pregnancy per
ET 740 (53.0%) 5 (45.5%) 2181 (48.5%) 22 (55.0%) 2782 (36.9%) 27 (45.0%)
Live-birth per ET 595 (44.5%) 4 (40.0%) 1728 (40.0%) 15 (42.9%) 1838 (25.2%) 13 (22.8%)
IVF (n = 31) GC (n = 5) IVF (n = 112) GC (n = 31) IVF (n = 260) GC (n = 50)
Cancelled cycle 0 (0%) 0 (0%) 10 (8.9%) 2 (6.5%) 20 (7.7%) 1 (2.0%)
Clinical pregnancy per
ET 7 (25.9%) 3 (75.0%) 33 (35.5%) 15 (53.6%) 61 (26.8%) 19 (40.4%)
Live-birth per ET 6 (23.1%) 3 (75.0%) 21 (24.7%) 11 (44.0%) 37 (16.6%) 8 (17.8%)
4(b) Cycles with a uterine factor infertility diagnosis (GC cycles n = 86 non-GC uterine factor cycles n = 403 )
IVF (n = 31) GC (n = 5) IVF (n = 112) GC (n = 31) IVF (n = 260) GC (n = 50)
Cancelled cycle 0 (0%) 0 (0%) 10 (8.9%) 2 (6.5%) 20 (7.7%) 1 (2.0%)
Clinical pregnancy per ET 7 (25.9%) 3 (75.0%) 33 (35.5%) 15 (53.6%) 61 (26.8%) 19 (40.4%)
Live-birth per ET 6 (23.1%) 3 (75.0%) 21 (24.7%) 11 (44.0%) 37 (16.6%) 8 (17.8%)
aValues presented are n (%) for categorical variables and mean ± SD for continuous variables. For GC cycles, the age is that of the intended parent.
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